{"@context":"https://schema.org/","@type":"Quiz","dateCreated":"2024-05-31T06:25:11.050Z","dateModified":"2024-07-19T09:20:51.229Z","typicalAgeRange":"11-18","educationalLevel":"GPAT","assesses":"Pathophysiology - Neoplastic diseases","educationalAlignment":[{"@type":"AlignmentObject","alignmentType":"educationalTopic","targetName":"Neoplastic diseases"},{"@type":"AlignmentObject","alignmentType":"educationalSubject","targetName":"Pathophysiology"},{"@type":"AlignmentObject","alignmentType":"educationalExam","targetName":"GPAT"}],"name":"Quiz about Neoplastic diseases","about":{"@type":"Thing","name":"Pathophysiology - Neoplastic diseases"},"hasPart":[{"@type":"Question","eduQuestionType":"Multiple choice","learningResourceType":"Practice problem","educationalLevel":"intermediate","name":"Question About Neoplastic diseases","text":"Trastuzumab is a/an","encodingFormat":"text/markdown","comment":{"@type":"Comment","text":"\"\""},"suggestedAnswer":[{"@type":"Answer","position":0,"encodingFormat":"text/markdown","text":"

EGFR/HER 2 inhibitor

","comment":{"@type":"Comment","text":"\"\""}},{"@type":"Answer","position":1,"encodingFormat":"text/markdown","text":"

Angiogenesis inhibitor

","comment":{"@type":"Comment","text":"\"\""}},{"@type":"Answer","position":2,"encodingFormat":"text/markdown","text":"

EGF Receptor HER inhibitor

","comment":{"@type":"Comment","text":"\"\""}},{"@type":"Answer","position":3,"encodingFormat":"text/markdown","text":"

BCR-ABL tyrosine kinase inhibitors

","comment":{"@type":"Comment","text":"\"\""}}],"acceptedAnswer":{"@type":"Answer","position":0,"encodingFormat":"text/markdown","text":"

EGFR/HER 2 inhibitor

","answerExplanation":{"@type":"text","text":"The correct option is (A):Trastuzumab, sold under the brand name Herceptin among others, is a monoclonal antibody used to treat breast cancer and stomach cancer."},"comment":{"@type":"Comment","text":"\"\""}}}]}

Trastuzumab is a/an

The Correct Option is A

Solution and Explanation

Top Questions on Neoplastic diseases

Questions Asked in GPAT exam